Business Wire

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research


Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships with nine of the top centers in the region, including Charité – Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), Universitätsspital Basel, Technische Universität München (TUM), Uniklinikum Erlangen, Universitätsklinikum Leipzig, Inselspital Bern, Universitätsklinik Mannheim-Heidelberg and Medizinische Universität Wien. These collaborations signify unparalleled representation of patient populations, representing 24% of all outpatient cases and 15% of the total patients in the DACH region.

This press release features multimedia. View the full release here:

Guillaume Bézie, Director of Partnerships Western Europe: “The Western Europe network covering France, Benelux and DACH represents the largest pool of centres for Owkin. Partnering with top academic institutions is an inevitable asset for our expansion strategy, and we are delighted to showcase the ability to significantly increase our footprint in the DACH region. By capturing the diverse landscape of human health, we empower our AI to better address the unique needs of all individuals. With our partners, we are fully committed to accelerate the secondary use of multimodal patient data for the purpose of giving the right treatment for each patient.”

By analyzing vast datasets and identifying complex patterns across the nine hospitals, Owkin will use its AI engines and diagnostic tools to improve patient outcomes in Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), and Cardiovascular Disease (CVD). This will enable researchers to discover novel biomarkers, predict treatment responses, and develop more effective therapies tailored to individual patients.

  • BiomarkerPlus (Outcome prediction): Owkin will work with Inselspital Bern, Technische Universität München (TUM) and Universitätsspital Basel to analyze multimodal patient data to identify which early-stage prostate cancer patients are most likely to fail primary curative treatment and ultimately progress to more severe disease and anticipate if they may benefit from a different management strategy. Owkin is also partnering with Uniklinikum Erlangen (UKER) on MIBC to analyze H&E slides to detect FGFR3 mutations.
  • TargetMatch (Target discovery): In partnership with Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität and Medizinische Universität Wien, Owkin will access a high-quality multimodal dataset, including digitized histology and RNA-seq, to better understand the response to treatment for neoadjuvant chemotherapy and to identify new targets and treatment strategies in MIBC.
  • TrialPlus (Clinical trial optimization): Owkin’s partnership with Universitätsklinikum Leipzig aims to use machine learning techniques to enhance clinical trial design for CVD.
  • AI Diagnostics (MSIntuit® CRC): To further improve Owkin’s first CE-IVD-approved MSI pre-screening tool MSIntuit® CRC, Owkin will work in close collaboration with Uniklinikum Erlangen (UKER) to validate our upgraded MSIntuit CRC V2 on more diverse cohorts.

In addition to advancing research towards more personalized treatment strategies for patients with prostate cancer, MIBC and CVD, Owkin has also expanded its MOSAIC network, a global initiative to build the world’s largest spatial omics dataset in oncology with 7,000 patient samples across 7 cancer indications, bringing on Uniklinikum Erlangen, Charité – Universitätsmedizin Berlin and Centre Hospitalier Universitaire Vaudois (CHUV) to accelerate research across numerous therapeutic areas.

Dr. Philipp Mann, Principal Partnerships Manager Switzerland, Germany and Austria (DACH) said: “The healthcare system across the DACH region is an invaluable asset because it offers an extensive repository of reliable, comprehensive health data that can guide drug discovery and development strategies. The collaboration between Owkin and these institutions enhances the use of this data, driving innovation and fast-tracking medical advancements. With the combined expertise of these partners, the data can be transformed into actionable insights used to revolutionize patient care and improve health outcomes.”

About Owkin

Owkin is the first end-to-end AI-biotech unicorn on a mission to understand complex biology and derive new multimodal biomarkers through AI. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing federated technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.

View source version on


(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Esri Press Book by Jack Dangermond Explores Creating a Better Future through Modern GIS17.7.2024 20:46:00 CEST | Press release

Esri, the global leader in location intelligence, today announced the publication next month of The Power of Where: A Geographic Approach to the World's Greatest Challenges. Written by Esri president Jack Dangermond with a dedicated Esri team and numerous contributors, this important new book explores the geographic approach—a way of solving problems using spatial analysis to perceive and understand patterns ranging from wildlife migration and rising seas to urban planning and food production. According to Dangermond, sustainability begins with geography. "I believed this when we started Esri, and I'm even more convinced today," says Dangermond. "GIS [geographic information system technology] provides a platform for addressing problems, exploring alternatives, designing solutions, and sharing them in a visual way that inspires action." The Power of Where shows through maps and stories how the growing GIS community is facing humanity's big challenges, including climate change, hunger, w

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting17.7.2024 18:00:00 CEST | Press release

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2 Therapy meeting taking place in Paris from September 4th to 7th, 2024. The presentation, entitled “EGL-003, a novel IL-2 mutein to selectively expand and activate regulatory T cells and improve therapeutic efficacy in autoimmune disease”, will show evidence that EGL-003, a non-targeted Fc-fused IL-2 agonist mutein, selectively binds to regulatory T cells (Treg) and induces Treg IL-2 signaling. The resulting increase of Treg frequencies was observed in vitro and in different mouse models. Accordingly, EGL-003 significantly improved clinical, macroscopic, and histological parameters in a DSS-induced colitis mouse model with expansion of tissue-resident Tregs. EGL-003 is the first drug candidate being developed for treatment of autoimmune diseases in Egle’s pipeline and h

Mouser Electronics Unlocks Game-Changing Human-Machine Interfaces in Latest Content Series17.7.2024 17:11:00 CEST | Press release

Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today released the latest installment of its Empowering Innovation Together (EIT) technology series, exploring the unique attributes of human-machine interfaces (HMI) for everyday devices and industrial applications. With the evolution of HMI, engineers are blending intuitive, user-centric designs with cutting-edge technologies to introduce a host of novel capabilities. In this series, Mouser takes a deeper look at the future technological and societal impact of HMIs across our devices, cars, houses, and each other. This press release features multimedia. View the full release here: Enter the world of HMI and Human Factors, where engineers and researchers delve into the psychological, physiological, and ergonomic aspects of designing interfaces for human-machine interaction to optimize user experi

LambdaTest Integrates Allure Reports with HyperExecute for Enhanced Test Reporting17.7.2024 17:00:00 CEST | Press release

LambdaTest, a leading cloud-based unified testing platform, is thrilled to announce the integration of Allure Reports with HyperExecute. This new integration aims to transform the test reporting landscape, offering a more streamlined, detailed, and visually appealing way to manage and review test results. Allure Framework is a versatile, lightweight, multi-language test reporting tool that provides a concise representation of tested functionalities through visually appealing web reports. It facilitates the easy extraction of valuable information for all stakeholders involved in the development process, enhancing collaboration and efficiency. For teams already utilizing Allure reports, the integration with HyperExecute allows for the seamless generation of consolidated Allure reports for each job. These reports are accessible through the report section of the HyperExecute dashboard, centralizing test insights and simplifying management. Additionally, HyperExecute users can enhance their

LTIMindtree Delivers 2.6% QoQ USD Revenue Growth in CC17.7.2024 16:40:00 CEST | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the first quarter ended June 30, 2024, as approved by its Board of Directors. “While the environment remains unchanged, fiscal 25 started on a positive note for us with Q1FY25 revenue of USD 1.1 billion, registering a 2.5% QoQ and 3.5% YoY revenue growth in USD terms. Our Q1FY25 EBIT expanded to 15% and order inflow remained stable at USD 1.4 billion. Our top 3 industry verticals and our largest geography have performed well sequentially. This is attributed to a measured uptick in IT spending for critical initiatives with clients balancing innovation and fiscal prudence.” -Debashis Chatterjee, Chief Executive Officer and Managing Director Key financial highlights: Quarter ended June 30, 2024 In USD: - Revenue at $1,096.2 million (+2.5% Q-o-Q / +3.5% Y-o-Y) - Net profit at $136.1 million (+2.8% Q-o-Q / -2.9% Y-o-Y) In INR: - Revenue at Rs 91,42

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye